Clinical Trials Directory

Trials / Completed

CompletedNCT02176044

The Effect of Nitric Oxide on Spatial Working Memory in Patients With Schizophrenia - Pilot Study

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
21 (actual)
Sponsor
King's College London · Academic / Other
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Not accepted

Summary

Spatial working memory (ability to remember where objects are in space) is impaired in patients with schizophrenia. It is thought that this impairment occurs due to problems with the chemical messenger (neurotransmitter), glutamate, and the N-methyl-D-aspartate (NMDA) glutamate receptor, particularly in the hippocampal brain region. NMDA receptor activation leads to increases in the release of the second messenger Nitric Oxide. Impaired NMDA receptor function would therefore be predicted to lead to reductions in Nitric Oxide production. Recent work suggests that a drug, sodium nitroprusside, which releases nitric oxide, enhances some aspects of cognition in schizophrenia (specifically related to negative symptoms). In this study, the investigators will test the hypothesis that sodium nitroprusside improves spatial working memory in patients with schizophrenia. 15 patients will receive sodium nitroprusside, and 15 will receive a nonactive compound (placebo). Their performance on a spatial working memory task will be tested before and after administration of sodium nitroprusside or placebo.

Conditions

Interventions

TypeNameDescription
DRUGSodium Nitroprusside infusion
OTHERPlacebo

Timeline

Start date
2014-08-01
Primary completion
2016-02-01
Completion
2016-02-01
First posted
2014-06-26
Last updated
2016-03-09

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT02176044. Inclusion in this directory is not an endorsement.

The Effect of Nitric Oxide on Spatial Working Memory in Patients With Schizophrenia - Pilot Study (NCT02176044) · Clinical Trials Directory